

PUBLISHED BY
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

Printed in Great Britain by Spottiswoode Ballantyne Ltd.
Colchester and London

AUTHOR INDEX

- ABDELHAMID, S., VECSEI, P., HAACK, D., GLESS, K.-H., WALB, D., LICHTWALD, K. & FIEGEL, P.** Dissociation in the excretion of different aldosterone metabolites and unmetabolized ('free') aldosterone in hypertension 409–414
- ALAGHBAND-ZADEH, J.**, see Eastwood, J.B. *et al.*
- ANDERSON, G.H., JR** Evidence that the acute cardiovascular response to isoprenaline is partly mediated via renin release 13–18
- ASATOOR, A.M., BENDING, M.R. & MILNE, M.D.** Peptiduria in experimental Fanconi syndrome in rats 277–279
- ATKINSON, J., BOILLAT, N., PERA-BALLY, R., PETERS-HAEFELI, L. & KIRCHERTZ, E.J.** Effect of chronic clonidine treatment and its abrupt cessation on mean blood pressure of rats with a normal or an elevated blood pressure 195–201
- BALLANTYNE, D.**, see Ballantyne, F.C. *et al.*
- BALLANTYNE, F.C., EPENETOS, A.A., CASLAKE, M., FORSYTHE, S. & BALLANTYNE, D.** The composition of low-density lipoprotein and very-low-density lipoprotein subfractions in primary hypothyroidism and the effect of hormone-replacement therapy 83–88
- BALLARD, F.J., TOMAS, F.M., POPE, L.M., HENDRY, P.G., JAMES, B.E. & MACMAHON, R.A.** Muscle protein degradation in premature human infants 535–544
- BARNES, S.**, see Engelking, L.R. *et al.*
- BAVIERA, E.**, see Rafestin-Oblin, M.E. *et al.*
- BELL, C. & McLACHLAN, E.M.** Dependence of deoxycorticosterone/salt hypertension in the rat on the activity of adrenergic cardiac nerves 203–210
- BELLINI, G., FIORENTINI, R., FERNANDES, M., ONESTI, G., HESSAN, H., GOULD, A.B., BIANCHI, M., KIM, K.E. & SWARTZ, C.** Neurogenic activity–angiotensin II interaction during the development and maintenance of renal hypertension in the rat 25–29
- BENDING, M.R.**, see Asatoor, A.M. *et al.*
- BENGIS, R.G. & COLEMAN, T.G.** Antihypertensive effect of prolonged blockade of angiotensin formation in benign and malignant, one- and two-kidney Goldblatt hypertensive rats 53–62
- BENNETT, R.M. & KOKOCINSKI, T.** Lactoferrin turnover in man 453–460
- BERTHELOT, P.**, see Pecker, F. *et al.*
- BIANCHI, M.**, see Bellini, G. *et al.*
- BILLING, B.H.**, see Gollan, J.L. *et al.*
- BOILLAT, N.**, see Atkinson, J. *et al.*
- BORN, W.**, see Dambacher, M.A. *et al.*
- BOUILLOU, R., GUESSENS, P., DEQUEKER, J. & DE MOOR, P.** Parathyroid function in primary osteoporosis 167–171
- BRERETON, P.J.**, see Wootton, R. *et al.*
- BRISSET, J.M.**, see Rafestin-Oblin, M.E. *et al.*
- BROOM, M.F.**, see Goulding, A. & Broom, M.F.
- BRUCE, C.**, see Charles, T.J. *et al.*
- BULLEN, A.W. & LOSOWSKY, M.S.** Editorial Review: Consequences of impaired splenic function 129–137
- BUSTOS, N.** see Del Batlle, A.M. *et al.*
- CAMERON, I.R.**, see Hall, R.J.C. & Cameron, I.R.
- CAMPBELL, M.J.**, see Morgan, M.H. *et al.*
- CANDY, D.C.A.**, see Cooper, B.T. *et al.*
- CARTER, G.D.**, see Eastwood, J.B. *et al.*
- CASLAKE, M.**, see Ballantyne, F.C. *et al.*
- CHARLES, T.J., WILLIAMS, S.J., SEATON, A., BRUCE, C. & TAYLOR, W.H.** Histamine, basophils and eosinophils in severe asthma 39–45
- CHUNG, Y.C., SILK, D.B.A. & KIM, Y.S.** Intestinal transport of a tetrapeptide, L-leucylglycylglycylglycine, in rat small intestine *in vivo* 1–11
- CLAIRE, M.**, see Rafestin-Oblin, M.E. *et al.*
- CLAMP, J.R. & GOUGH, M.** Study of the oligosaccharide units from mucos glycoproteins of meconium from normal infants and from cases of cystic fibrosis with meconium ileus 445–451
- CLARK, M.B.**, see Wootton, R. *et al.*
- CLARK, T.J.H.**, see Higenbottam, T. & Clark, T.J.H.
- CLARKE, E.W., JAMISON, J.P. & QUARTEY-PAPAFIO, J.B.** Impairment of flow in routine gravity-fed intravenous infusions to surgical patients 515–520

- COLEMAN, T.G., see Bengis, R.G. & Coleman, T.G.; see also Norman, R.A., Jr *et al.*
- COLINA-CHOURIO, J., MCGIFF, J.C. & NASJLETTI, A. Effect of indomethacin on blood pressure in the normotensive unanaesthetized rabbit: possible relation to prostaglandin synthesis inhibition 359-365
- COLLINGS, L., see Linnell, J.C. *et al.*
- COOPER, B.T., CANDY, D.C.A., HARRIES, J.T. & PETERS, T.J. Subcellular fractionation studies of the intestinal mucosa in congenital sucrase-isomaltase deficiency 181-185
- CORVOL, P., see Nakane, H. *et al.*; see also Rafestin-Oblin, M.E. *et al.*
- CRAWFORD, G.A., SAVDIE, E. & STEWART, J.H. Heparin-released plasma lipases in chronic renal failure and after renal transplantation 155-165
- DALY, A., see Eastwood, J.B. *et al.*
- DAMBACHER, M.A., FISCHER, J.A., HUNZIKER, W.H., BORN, W., MORAN, J., ROTH, H.-R., DELVIN, E.E. & GLORIEUX, F.H. Distribution of circulating immunoreactive components of parathyroid hormone in normal subjects and in patients with primary and secondary hyperparathyroidism: the role of the kidney and of the serum calcium concentration 435-443
- DASHER, C.A., see Engelking, L.R. *et al.*
- DAWSON, J., SEYMOUR, C.A. & PETERS, T.J. Gilbert's syndrome: analytical subcellular fractionation of liver biopsy specimens. Enzyme activities, organelle pathology and evidence for subpopulations of the syndrome 491-497
- DE JONG, W., see Ten Berg, R.G.M. *et al.*
- DEL BATTLE, A.M., WIDER DE XIFRA, E.A., STELLA, A.M., BUSTOS, N. & WITH, T.K. Studies on porphyrin biosynthesis and the enzymes involved in bovine congenital erythropoietic porphyria 63-70
- DELVIN, E.E., see Dambacher, M.A. *et al.*
- DE MOOR, P., see Bouillon, R. *et al.*
- DEQUEKER, J., see Bouillon, R. *et al.*
- DERKX, F.H.M., TAN-TJIONG, H.L., MAN IN 'T VELD, A.J., SCHALEKAMP, M.P.A. & SCHALEKAMP, M.A.D.H. Activation of inactive plasma renin by plasma and tissue kallikreins 351-357
- DE WARDENER, H.E., see Eastwood, J.B. *et al.*
- DLOUHA, H., KŘEČEK, J. & ZICHA, J. Effect of age on hypertensive stimuli and the development of hypertension in Brattleboro rats 273-275
- DOLLERY, C.T., see Maling, T.J.B. *et al.*
- DOWN, M.C., see Linnell, J.C. *et al.*
- DUVALDESTIN, P., see Pecker, F. *et al.*
- EASTWOOD, J.B., DALY, A., CARTER, G.D., ALAGHBAND-ZADEH, J. & DE WARDENER, H.E. Plasma 25-hydroxy-vitamin D in normal subjects and patients with terminal renal failure, on maintenance haemodialysis and after transplantation 473-476
- EDWARDS, R.H.T., see Wiles, C.M. *et al.*
- EISENREICH, M., see Meyer, D.K. *et al.*
- ELIA, M., OPPENHEIM, W.L., SMITH, R., ILIC, V. & WILLIAMSON, D.H. Changes in blood glucose and plasma insulin after intravenous galactose in human injury 249-256
- ENGELKING, L.R., BARNES, S., DASHER, C.A., NAFTEL, D.C. & HIRSCHOWITZ, B.I. Radio-labelled bile acid clearance in control subjects and patients with liver disease 499-508
- ENGLAND, J.M., see Linnell, J.C. *et al.*
- EPENETOS, A.A., see Ballantyne, F.C. *et al.*
- ESNOUF, M.P., see Falconer Smith, J.F. *et al.*
- FALCONER SMITH, J.F., VAN HEGAN, R.I., ESNOUF, M.P. & ROSS, B.D. Characteristics of renal handling of human immunoglobulin light chain by the perfused rat kidney 113-120
- FERNANDES, M., see Bellini, G. *et al.*
- FIEGEL, P., see Abdelhamid, S. *et al.*
- FIORENTINI, R., see Bellini, G. *et al.*
- FISCHER, J.A., see Dambacher, M.A. *et al.*
- FORSYTHE, S., see Ballantyne, F.C. *et al.*
- FRANCIS, M.J.O., see Pointon, J.J. *et al.*
- FRY, C.H., see Poole-Wilson, P.A. *et al.*
- FUNAKAWA, S., see Kawamura, M. *et al.*
- GALINDEZ, E., see Poole-Wilson, P.A. *et al.*
- GANAPATHY, V. & RADHAKRISHNAN, A.N. Interaction of amino acids with glycyl-L-leucine hydrolysis and transport in monkey small intestine 521-527
- GARDNER, M.L.G. Superficial or membrane digestion of peptides in dinitrophenol-inhibited rat small intestine 217-220
- GARDNER, M.L.G. & PLUMB, J.A. Release of dipeptide hydrolase activities from rat small intestine perfused *in vitro* and *in vivo* 529-534
- GUESENS, P., see Bouillon, R. *et al.*
- GLESS, K.-H., see Abdelhamid, S. *et al.*
- GLORIEUX, F.H., see Dambacher, M.A. *et al.*
- GOLDEN, M.H.N. see Taruvinga, M. *et al.*

- GOLLAN, J.L., HOLE, D.R. & BILLING, B.H. The role of dietary lipid in the regulation of unconjugated hyperbilirubinaemia in Gunn rats 327-337
- GORDON, D. & PEART, W.S. Sodium excretion in man, and adaptation to a low-sodium diet: effect of intravenous sodium chloride 225-231
- GOUGH, M., see Clamp, J.R. & Gough, M.
- GOULD, A.B., see Bellini, G. *et al.*
- GOULDING, A. & BROOM, M.F. Effects of diphosphonate and colchicine administration upon acid-base changes induced in rats by bilateral nephrectomy 19-23
- GUPTA, V.J., see Wilcken, D.E.L. & Gupta, V.J.
- HAACK, D., see Abdelhamid, S. *et al.*
- HALL, R.J.C. & CAMERON, I.R. The effect of pentobarbitone on plasma and intracellular sodium, potassium and pH in rabbit cardiac and skeletal muscle 549-551
- HAMILTON, C.A., see Jones, D.H. *et al.*; see also Maling, T.J.B. *et al.*
- HANES, F.A., see Robertson, W.G. *et al.*
- HANOUNE, J., see Pecker, F. *et al.*
- HARRIES, J.T., see Cooper, B.T. *et al.*
- HARRISON, B.D.W., see Rudolf, M. *et al.*
- HATA, T., see Ogihara, T. *et al.*
- HENDRY, P.G., see Ballard, F.J. *et al.*
- HESP, R., WILLIAMS, D., RINSLER, M. & REEVE, J. A comparison of chromium sesquioxide and [⁵¹Cr]chromic chloride as inert markers in calcium balance studies 89-92
- HESP, R., see also Wootton, R. *et al.*
- HESSAN, H., see Bellini, G. *et al.*
- HEYBURN, P.J., see Robertson, W.G. *et al.*
- HIGENBOTTAM, T. & CLARK, T.J.H. A method for standardizing airway resistance for variations in lung volume 397-400
- HILTON, P.J., see Patrick, J. & Hilton, P.J.
- HIRSCHOWITZ, B.I., see Engelking, L.R. *et al.*
- HODGKINSON, A., MARSHALL, D.H. & NORDIN, B.E.C. Vitamin D and magnesium absorption in man 121-123
- HODKINSON, H.M., see Wootton, R. *et al.*
- HOLE, D.R., see Gollan, J.L. *et al.*
- HOPWOOD, J.J. & MULLER, V. Biochemical discrimination of Hurler and Scheie syndromes 265-272
- HUNZIKER, W.H., see Dambacher, M.A. *et al.*
- IKEMOTO, F., see Kawamura, M. *et al.*
- ILIC, V., see Elia, M. *et al.*
- JACKSON, A.A., see Taruvinga, M. *et al.*
- JAMES, B.E., see Ballard, F.J. *et al.*
- JAMISON, J.P., see Clarke, E.W. *et al.*
- JONES, D.A., see Wiles, C.M. *et al.*
- JONES, D.H., HAMILTON, C.A. & REID, J.L. Choice of control groups in the appraisal of sympathetic nervous activity in essential hypertension 339-344
- JONES, D.H., see also Watson, R.D.S. *et al.*
- KANE, S.P. & VINCENTI, A.C. Mucosal enzymes in human inflammatory bowel disease with reference to neutrophil granulocytes as mediators of tissue injury 295-303
- KASTNER, P.R., see Norman, R.A. *et al.*
- KATZ, A.I., see Koeppen, B.M. *et al.*
- KAWAMURA, M., IKEMOTO, F., FUNAKAWA, S. & YAMAMOTO, K. Characteristics of a renin-binding substance for the conversion of renin into a higher-molecular-weight form in the dog 345-350
- KIM, K.E., see Bellini, G. *et al.*
- KIM, Y.S., see Chung, Y.C. *et al.*
- KIRCHERTZ, E.J., see Atkinson, J. *et al.*
- KLENERMAN, L., see Wootton, R. *et al.*
- KOEPPEN, B.M., KATZ, A.I. & LINDHEIMER, M.D. Effect of general anaesthesia on renal haemodynamics in the rat 469-471
- KOKOCINSKI, T., see Bennett, R.M. & Kokocinski, T.
- KREČEK, J., see Dlouha, H. *et al.*
- KUMAHARA, Y., see Ogihara, T. *et al.*
- LASZLO, G., see Latimer, R.D. & Laszlo, G.
- LATIMER, R.D. & LASZLO, G. Carbon dioxide equilibration in canine lungs during rebreathing and acute alkalosis 385-388
- LAYCOCK, J.F., see Walter, S.J. *et al.*
- LEE, G. DE J., see Prichard, J.S. & Lee, G. de J.
- LEENEN, F.H.H., see Ten Berg, R.G.M. *et al.*
- LICHTWALD, K., see Abdelhamid, S. *et al.*
- LINDHEIMER, M.D., see Koeppen, B.M. *et al.*
- LINNELL, J.C., COLLINGS, L., DOWN, M.C. & ENGLAND, J.M. Distribution of endogenous cobalamin between the transcobalamins in various mammals 139-144
- LITTLLER, W.A., see Watson, R.D.S. *et al.*; see also Watson, R.D.S. *et al.*
- LLEWELYN, D.E.H. Mathematical analysis of the diagnostic relevance of clinical findings 477-479
- LOSOWSKY, M.S., see Bullen, A.W. & Losowsky, M.S.

- LUNDHOLM, K. & SCHERSTÉN, T. Protein synthesis in isolated human skeletal muscle tissue: evaluation of an experimental model 221–223
- MCCONNELL, J.B., MURISON, J. & STEWART, W.K. The role of the colon in the pathogenesis of hyperchloraemic acidosis in uretersigmoid anastomosis 305–312
- MCGIFF, J.C., see Colina-Chourio, J. *et al.*
- MCLACHLAN, E.M., see Bell, C. & McLachlan, E.M.
- MACMAHON, R.A., see Ballard, F.J. *et al.*
- MALING, T.J.B., DOLLERY, C.T. & HAMILTON, C.A. Clonidine and sympathetic activity during sleep 509–514
- MANDAI, T., see Ogihara, T. *et al.*
- MAN IN 'T VELD, A.J. see Derkx, F.H.M. *et al.*
- MARSHALL, D.H., see Hodgkinson, A. *et al.*
- MARUYAMA, A., see Ogihara, T. *et al.*
- MENARD, J., see Nakane, H. *et al.*
- MENDELSOHN, F.A.O. Evidence for the local occurrence of angiotensin II in rat kidney and its modulation by dietary sodium intake and converting enzyme blockade 173–179
- MEYER, D.K., EISENREICH, M. & NUTTO, D. Effect of isoprenaline on the plasma concentrations of angiotensin III in rats 401–407
- MICHAUD, A., see Rafestin-Oblin, M.E. *et al.*
- MIKAMI, H., see Ogihara, T. *et al.*
- MILNE, M.D., see Asatoor, A.M. *et al.*
- MORAN, J., see Dambacher, M.A. *et al.*
- MORGAN, M.H., READ, A.E. & CAMPBELL, M.J. Clinical and electrophysiological studies of peripheral nerve function in patients with chronic liver disease 31–37
- MULLER, V., see Hopwood, J.J. & Muller, V.
- MURISON, J., see McConnell, J.C. *et al.*
- NAFTEL, D.C., see Engelking, L.R. *et al.*
- NAKAMARU, M., see Ogihara, T. *et al.*
- NAKANE, H., NAKANE, Y., CORVOL, P. & MENARD, J. Effect of acid, trypsin and cold treatment and of renin–plasma interaction on the activity of renin secreted by rat kidney 233–240
- NAKANE, Y., see Nakane, H. *et al.*
- NASJLETTI, A., see Colina-Chourio, J. *et al.*
- NORDIN, B.E.C., see Hodgkinson, A. *et al.*
- NORMAN, R.A., JR, COLEMAN, T.G. & KASTNER, P.R. Urine reinfusion diuresis and natriuresis in rats; role of water, electrolyte and urea 187–193
- NUTTO, D., see Meyer, D.K. *et al.*
- OGIHARA, T., HATA, T., MARUYAMA, A., MIKAMI, H., NAKAMARU, M., MANDAI, T. & KUMAHARA, Y. Studies on the renin–angiotensin–aldosterone system in elderly hypertensive patients with an angiotensin II antagonist 461–463
- ONESTI, G., see Bellini, G. *et al.*
- OPPENHEIM, W.L., see Elia, M. *et al.*
- PAGE, A.J.F., see Watson, R.D.S. *et al.*
- PATRICK, J. & HILTON, P.J. Editorial Review: Characterization of sodium-transport disorders in disease: different effects upon sodium and potassium of changes in the sodium pump and in membrane permeability 289–293
- PEACOCK, M., see Robertson, W.G. *et al.*
- PEART, W.S., see Gordon, D. & Peart, W.S.
- PECKER, F., DUVALDESTIN, P., BERTHELOT, P. & HANOUNE, J. The adenylate cyclase system in human liver: characterization, subcellular distribution and hormonal sensitivity in normal or cirrhotic adult, and in foetal liver 313–325
- PERA-BALLY, R., see Atkinson, J. *et al.*
- PETERS, T.J., see Cooper, B.T. *et al.*; see also Dawson, J. *et al.*
- PETERS-HAEFELI, L., see Atkinson, J. *et al.*
- PLUMB, J.A., see Gardner, M.L.G. & Plumb, J.A.
- POINTON, J.J., FRANCIS, M.J.O. & SMITH, R. Effect of vitamin D deficiency on sarcoplasmic reticulum function and troponin C concentration of rabbit skeletal muscle 257–263
- POOLE-WILSON, P.A., GALINDEZ, E. & FRY, C.H. Effect of ouabain in therapeutic concentration on K⁺ exchange and contraction of human and rabbit myocardium 415–420
- POPE, L.M., see Ballard, F.J. *et al.*
- PRICHARD, J.S. & LEE, G. DE J. Measurement of water distribution and transcapillary solute flux in dog lung by external radioactivity counting 145–154
- QUARTEY-PAPAFIO, J.B., see Clarke, E.W. *et al.*
- RADHAKRISHNAN, A.N., see Ganapathy, V. & Radhakrishnan, A.N.
- RAFESTIN-OBLIN, M.E., ROTH-MEYER, C., CLAIRE, M., MICHAUD, A., BAVIERA, E. BRISSET, J.M. & CORVOL, P. Are mineralocorticoid receptors present in human renal adenocarcinoma? 421–425
- READ, A.E., see Morgan, M.H. *et al.*

- REEVE, J., see Hesp, R. *et al.*; see also Wootton, R. *et al.*
- REID, J.L., see Jones, D.H. *et al.*; see also Watson, R.D.S. *et al.*
- RINSLER, M., see Hesp, R. *et al.*
- RIORDAN, J.F., see Rudolf, M. *et al.*
- ROBERTSON, W.G., HEYBURN, P.J., PEACOCK, M., HANES, F.A. & SWAMINATHAN, R. The effect of high animal protein intake on the risk of calcium stone-formation in the urinary tract 285–288
- ROSS, B.D. & TANNEN, R.L. Effect of decrease in bicarbonate concentration on metabolism of the isolated perfused rat kidney 103–111
- ROSS, B.D., see also Falconer Smith, J.F. *et al.*
- ROTH, H.-R., see Dambacher, M.A. *et al.*
- ROTH-MEYER, C., see Rafestin-Oblin, M.E. *et al.*
- RUDOLF, M., TURNER, J.A.McM., HARRISON, B.D.W., RIORDAN, J.F. & SAUNDERS, K.B. Changes in arterial blood gases during and after a period of oxygen breathing in patients with chronic hypercapnic respiratory failure and in patients with asthma 389–396
- SAUNDERS, K.B., see Rudolf, M. *et al.*
- SAVDIE, E., see Crawford, G.A. *et al.*
- SCHALEKAMP, M.A.D.H., see Derkx, F.H.M. *et al.*
- SCHALEKAMP, M.P.A., see Derkx, F.H.M. *et al.*
- SCHERSTÉN, T., see Lundholm, K. & Scherstén, T.
- SEATON, A., see Charles, T.J. *et al.*
- SEYMOUR, C.A., see Dawson, J. *et al.*
- SHIRLEY, D.G., see Walter, S.J. *et al.*
- SILK, D.B.A., see Chung, Y.C. *et al.*
- SLAVIN, G., see Wootton, R. *et al.*
- SMITH, R., see Elia, M. *et al.*; see also Pointon, J.J. *et al.*
- SORRELL, M.F. & TUMA, D.J. Editorial Review: Effect of alcohol on hepatic metabolism: selected aspects 481–489
- STALLARD, T.J., see Watson, R.D.S. *et al.*
- STELLA, A.M., see Del Batlle, A.M. *et al.*
- STEWART, J.H., see Crawford, G.A. *et al.*
- STEWART, W.K., see McConnell, J.B. *et al.*
- SWAMINATHAN, R., see Robertson, W.G. *et al.*
- SWARTZ, C., see Bellini, G. *et al.*
- TANNEN, R.L., see Ross, B.D. & Tannen, R.L.
- TAN-TJIONG, H.L., see Derkx, F.H.M. *et al.*
- TARUVINGA, M., JACKSON, A.A. & GOLDEN, M.H.N. Comparison of ¹⁵N-labelled glycine, aspartate, valine and leucine for measurement of whole-body protein turnover 281–283
- TAYLOR, E.A., see Trembach, P.W. *et al.*
- TAYLOR, W.H., see Charles, T.J. *et al.*
- TELLEZ-YUDILEVICH, M., see Wootton, R. *et al.*
- TEN BERG, R.G.M., LEENEN, F.H.H. & DE JONG, W. Plasma renin activity and sodium, potassium and water excretion during reversal of hypertension in the one-clip, two-kidney hypertensive rat 47–52
- TOMAS, F.M., see Ballard, F.J. *et al.*
- TREMBATH, P.W., TAYLOR, E.A., VARLEY, J. & TURNER, P. Effect of propranolol on the ventilatory response to hypercapnia in man 465–468
- TUMA, D.J., see Sorrell, M.F. & Tuma, D.J.
- TURNER, J.A.McM., see Rudolf, M. *et al.*
- TURNER, P., see Trembach, P.W. *et al.*
- WALB, D., see Abdelhamid, S. *et al.*
- WALTER, S.J., LAYCOCK, J.F. & SHIRLEY, D.G. A micropuncture study of proximal tubular function after acute hydrochlorothiazide administration to Brattleboro rats with diabetes insipidus 427–434
- WALTON, R.J. Effect of intravenous sodium lactate on renal tubular reabsorption of phosphate in man 125–127
- WATSON, R.D.S., PAGE, A.J.F., LITTLER, W.A., JONES, D.H. & REID, J.L. Plasma noradrenaline concentrations at different vascular sites during rest and isometric and dynamic exercise 545–547
- WATSON, R.D.S., STALLARD, T.J. & LITTLER, W.A. Effects of β-adrenoreceptor antagonists on sino-aortic baroreflex sensitivity and blood pressure in hypertensive man 241–247
- WEN, SUNG-FENG Effect of phlorhizin on renal glucose and phosphate transport in the dog 367–374
- WIDER DE XIFRA, E.A., see Del Batlle, A.M. *et al.*
- WILCKEN, D.E.L. & GUPTA, V.J. Cysteine–homocysteine mixed disulphide: differing plasma concentrations in normal men and women 211–215
- WILES, C.M., YOUNG, A., JONES, D.A. & EDWARDS, R.H.T. Muscle relaxation rate, fibre-type composition and energy turnover in hyper- and hypo-thyroid patients 375–384
- WILLIAMS, D., see Hesp, R. *et al.*
- WILLIAMS, S.J., see Charles, T.J. *et al.*
- WILLIAMSON, D.H., see Elia, M. *et al.*
- WITH, T.K., see Del Batlle, A. M. *et al.*
- WOOTTON, R., BRERETON, P.J., CLARK, M.B., HESP, R., HODKINSON, H.M., KLENERMAN, L., REEVE, J., SLAVIN, G. & TELLEZ-

- YUDILEVICH, M. Fractured neck of femur in the elderly: an attempt to identify patients at risk 93-101
- VAN HEGAN, R.I., see Falconer Smith, J.F. *et al.*
- VARLEY, J., see Trembath, P.W. *et al.*
- VECSEI, P., see Abdelhamid, S. *et al.*
- VINCENTI, A.C., see Kane, S.P. & Vincenti, C.A.
- YAMAMOTO, K., see Kawamura, M. *et al.*
- YOUNG, A., see Wiles, C.M. *et al.*
- ZICHA, J., see Dlouha, H. *et al.*
- ZIMMERMAN, B.G. Absence of adrenergic mediation of agonist response to [Sar¹, Ala⁸]angiotensin II in conscious normotensive and hypertensive dogs 71-81

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.

Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption, intestinal
 - calcium 121–123
 - magnesium 121–123
 - peptides 217–220
 - vitamin D 121–123
- Absorption, renal, phosphate and sodium lactate 125–127
- Acid–base balance
 - pulmonary carbon dioxide equilibration 385–388
- Acidosis
 - hyperchloraemic 305–312
 - isolated kidney 103–111
 - nephrectomy 19–23
 - uretersigmoid anastomosis 305–312
- Adenocarcinoma, renal
 - mineralocorticoid receptors 421–425
- Adenosine triphosphate, sodium-transport disorders 289–293
- Adenylate cyclase, liver 313–325
- β -Adrenoreceptor
 - antagonists 241–247
 - blockade 203–210
 - isoprenaline stimulation 13–18
- Age, hypertensive responses 273–275
- Airway conductance 397–400
- Airway resistance 397–400
- Albumin, serum, pulmonary water compartments 145–154
- Alcohol, hepatic metabolism 481–490*
- Aldosterone
 - angiotensin II antagonist 461–463
 - receptors in renal adenocarcinoma 421–425
 - urinary excretion 409–414
- Aldosterone-18-glucuronide, urinary excretion 409–414
- Alkalosis, pulmonary carbon dioxide equilibration 385–388
- Alveolar–arterial difference 385–388
- Amino acids
 - intestinal transport 521–527
 - sex difference in plasma concentrations 211–215
 - skeletal muscle proteins 221–223
- δ -Aminolaevulinate dehydratase, bovine congenital erythropoietic porphyria 63–70
- δ -Aminolaevulinate synthase, bovine congenital erythropoietic porphyria 63–70
- Aminopeptidase, jejunal 1–11
- Ammonia
 - excretion in uretersigmoid anastomosis 305–312
 - metabolism of isolated kidney 103–111
- Anaemia, inflammation 453–460
- Anaesthesia
 - pentobarbitone 549–551
 - renal haemodynamics 469–471
- Angiotensin II
 - antagonist 25–29, 71–81, 461–463
 - inhibition of formation 53–62
 - kidney 173–179
- Angiotensin III
 - isoprenaline 401–407
- Antidiuresis, hydrochlorothiazide 427–434
- Arterial pressure
 - indometacin 359–365
 - renin 13–18
- Arterial pressure *see also* Hypertension
- Artery, noradrenaline concentration 545–547
- Aspartate, whole-body protein turnover 281–283
- Asthma
 - basophils, eosinophils and histamine 39–45
 - blood gases 389–396
- Asucrasia 181–185
- Baroreflex, sino-aortic 241–247
- Basophils, asthma 39–45
- Bayes' theorem 477–479
- Bence-Jones protein, isolated kidney 113–120
- Bicarbonate
 - excretion in uretersigmoid anastomosis 305–312
 - metabolism of isolated kidney 103–111
- Bile acid clearance 499–508
- Bilirubin, metabolism 327–337
- Biochemical discrimination, Hurler and Scheie syndromes 265–272
- Blood flow, general anaesthesia 469–471

Subject Index

- Blood pressure
 indomethacin 359–365
 renin 13–18
- Blood pressure *see also* Hypertension
- Bone marrow, porphyrin biosynthesis 63–70
- Bone
 acid-base buffering 19–23
 femur fractures in elderly 93–101
 osteoporosis 167–171
- Brush border, intestinal
 disaccharidases 181–185
 α -glucosidase 181–185
 peptide hydrolysis 217–220
- Bull with congenital erythropoietic porphyria 63–70
- Calcium
 absorption and vitamin D 121–123
 balance studies 89–92
 kinetics 93–101
 parathyroid hormone 435–443
 protein and urinary output 285–288
- Calculi, urinary
 dietary protein 285–288
- Carbon dioxide
 propranolol 465–468
 pulmonary equilibration 385–388
- Cardiac muscle *see* Myocardium
- Catecholamines
 excretion 339–344
 metabolism 203–210
 saralasin 71–81
- Cell-membrane permeability 289–293*
- Cholestasis 499–508
- Cholic acid clearance 499–508
- Chromic chloride, calcium balance studies 89–92
- Chromium sesquioxide, calcium balance studies 89–92
- Clonidine
 blood pressure 195–201
 sympathetic activity during sleep 509–514
- Cobalamin
 endogenous 139–144
- Colchicine
 acid-base balance 19–23
- Colitis, mucosal enzymes 295–303
- Colon, pathogenesis of hyperchloraemic acidosis 305–312
- Congenital porphyria, enzymes 63–70
- Contraction, myocardium 415–420
- Converting enzyme
 renal hypertension 53–62
 sodium intake 173–179
- Covariance analysis of airway resistance 397–400
- Creatinine, premature infants 535–544
- Cysteine–homocysteine, plasma concentrations 211–215
- Cystic fibrosis with meconium ileus 445–451
- Cytosol, kidney renin 345–350
- Deoxycorticosterone, hypertension 203–210
- Dexamethasone binding in renal adenocarcinoma 421–425
- Diabetes insipidus
 hydrochlorothiazide 427–434
 hypertension 273–275
- Diagnosis by elimination 477–479
- Diet
 low-sodium 225–231
 protein and urinary calculi 285–288
- 2,4-Dinitrophenol inhibition of intestinal absorption 217–220
- Diphosphonate
 acid-base balance 19–23
 skeletal muscle 257–263
- Disaccharidases, jejunal 181–185
- Diuresis, urine reinfusion 187–193
- Diuretics, immunoglobulin light chain in kidney 113–120
- Electroencephalography, peripheral nerve function 31–37
- Electrolytes, anaesthesia 549–551
- Endoplasmic reticulum, hepatic 491–497
- Energy turnover 375–384
- Enterocyte, subcellular fractionation 181–185
- Eosinophils, asthma 39–45
- Erythrocyte, morphology in hypoplasia 129–137*
- Ethanol, hepatic metabolism 481–490*
- Exercise
 dynamic 545–547
 isometric 545–547
- External radioactivity counting 145–154
- Fanconi syndrome 277–279
- Femur, fractures in elderly 93–101
- Ferrokinetics 453–460
- Fracture, bone, in elderly 93–101
- Functional residual capacity 397–400
- Galactose
 blood glucose 249–256
 plasma insulin 249–256
- Gilbert's disease 491–497

- Gluconeogenesis, acidosis in isolated kidney 103–111
- Glucose transport, renal 367–374
- Glutamine, metabolism in isolated kidney 103–111
- Glycine, whole-body protein turnover 281–283
- Glycocholic acid clearance 499–508
- Glycoproteins
- meconium mucus 445–451
 - metabolism and ethanol 481–490*
- Glycyl-L-leucine hydrolysis and transport 521–527
- Gunn rat, unconjugated hyperbilirubinaemia 327–337
- Haemodialysis, plasma 25-hydroxy-vitamin D 473–476
- Haemodynamics, renal 469–471
- Heparin, plasma lipases 155–165
- Hip replacement, intravenous galactose 249–256
- Histamine, asthma 39–45
- Homocystinuria and cysteine–homocysteine 211–215
- Hormones
- insulin 221–223
 - parathyroid hormone 167–171, 435–443
 - thyroxine 83–88
- Hurler syndrome 265–272
- Hydrochlorothiazide 427–434
- 18-Hydroxycorticosterone, urinary excretion 409–414
- Hydroxyproline, Fanconi syndrome 277–279
- 25-Hydroxy-vitamin D
- femur fractures in elderly 93–101
 - primary osteoporosis 167–171
 - seasonal variation 473–476
- Hyperaldosteronism 409–414
- Hyperbilirubinaemia
- hereditary 491–497
 - unconjugated 327–337
- Hypercapnia
- chronic 389–396
 - propranolol 465–468
- Hyperparathyroidism 435–443
- Hypertension
- β -adrenoceptor antagonists 241–247
 - age 273–275
 - aldosterone excretion 409–414
 - angiotensin II antagonist 461–463
 - clonidine 195–201
 - indomethacin 359–365
 - outpatients 339–344
- Hypertension, experimental
- aortic ligation 25–29
- Hypertension, experimental
- deoxycorticosterone salt 203–210
 - neurogenic activity 25–29
 - renal, Goldblatt one-kidney one-clip 53–62
 - renal, Goldblatt two-kidney one-clip 47–52, 53–62, 71–81
- Hypertension, renovascular
- angiotensin blockade 53–62, 71–81
 - plasma renin activity 47–52
 - potassium excretion 47–52
 - sodium excretion 47–52
 - water excretion 47–52
- Hyperthyroidism, quadriceps function 375–384
- Hyposplenism 129–137*
- Hypothyroidism
- plasma lipoproteins 83–88
 - quadriceps function 375–384
- Hypoxaemia 389–396
- α -L-Iduronidase, Hurler and Scheie syndromes 265–272
- Immune responses, spleen 129–137*
- Immunoglobulin light chain, isolated kidney 113–120
- Indomethacin 359–365
- Injury
- intravenous galactose 249–256
 - neutrophil granulocytes 295–303
- Insulin, skeletal muscle protein synthesis 221–223
- Intestine
- amino acid transport 521–527
 - dipeptide hydrolases 529–534
 - malabsorption 181–185
 - peptide absorption 217–220
 - subcellular fractionation 181–185
 - transport 1–11, 521–527
- Intravenous infusions 225–231, 515–520
- Isomaltase, intestinal 181–185
- Isoprenaline, angiotensin III 401–407
- Jejunum
- aminopeptidase 1–11
 - disaccharidases 181–185
 - subcellular fractionation 181–185
 - transport 1–11
- Juxtaglomerular apparatus 173–179
- Kallikrein
- inhibitor 351–357
 - renin activation 351–357
- Kidney
- acid–base changes after nephrectomy 19–23
 - ammonia production 103–111
 - anaesthesia and haemodynamics 469–471

- Kidney**
- angiotensin II 173–179
 - blood flow 71–81
 - cortical homogenate renin 345–350
 - failure 155–165, 435–443
 - glucose transport 367–365
 - immunoglobulin light chain 113–120
 - indomethacin 359–365
 - juxtaglomerular apparatus 173–179
 - mineralocorticoid receptors 421–425
 - phosphate absorption and lactate 125–127
 - phosphate transport 367–374
 - plasma 25-hydroxy-vitamin D 473–476
 - porphyrin biosynthesis 63–70
 - protein transport 113–120
 - proximal tubular function 427–434
 - renin secretion 233–240
 - sodium transport 367–374
 - transplantation and lipases 155–165
- Kidney disease**
- chronic renal failure 155–165, 435–443
 - immunoglobulin light chain 113–120
 - plasma 25-hydroxy-vitamin D 473–476
- Lactase, intestinal 181–185
- Lactate, sodium, phosphate renal absorption 125–127
- Lactoferrin turnover 453–460
- Leucine, whole-body protein turnover 281–283
- Leucocytes
- asthma 39–45
 - tissue injury 295–303
- L-Leucylglycylglycylglycine, intestinal transport I–II
- Lipase, plasma 155–165
- Lipid
- hyperbilirubinaemia 327–337
 - metabolism and ethanol 481–490*
- Lipoprotein, plasma, primary hypothyroidism 83–88
- Liver
- adenylate cyclase system 315–325
 - bile acid clearance 499–508
 - ethanol 481–490*
 - foetal 313–325
 - function tests 31–37
 - hyperglycaemia 249–256
 - porphyrin biosynthesis 63–70
 - subcellular fractionation 491–497
- Liver disease
- bile acid clearance 499–508
 - cirrhosis 31–37, 313–325, 481–490*
 - Gilbert's syndrome 491–497
 - peripheral nerve function in 31–37
- Lung**
- carbon dioxide equilibration 385–388
 - functional residual capacity 397–400
 - volume 397–400
 - water compartments 145–154
- Lysosomes in Gilbert's syndrome 491–497
- Macula densa 173–179
- Magnesium, absorption and vitamin D 121–123
- Maleic acid, Fanconi syndrome 277–279
- Maltase, intestinal 181–185
- Mathematical analysis of clinical diagnosis 477–479
- Meconium mucus glycoproteins 445–451
- Membrane, liver 313–325
- Membrane digestion
- intestinal 217–220
 - permeability 289–293*
- Metabolism, calcium balance 89–92
- 3-Methylhistidine, premature infants 535–544
- Mineralocorticoid receptors in renal adenocarcinoma 421–425
- Mixed disulphide, plasma 211–215
- Mucus glycoproteins of meconium 445–451
- Muramidase, rectal mucosa 295–303
- Muscle-fibre types 375–384
- Muscle, skeletal
- energy turnover 375–384
 - fibre-type composition 375–384
 - pentobarbitone anaesthesia 549–551
 - protein degradation 535–544
 - protein synthesis 221–223
 - relaxation rate 375–384
 - thyroid disorders 375–384
 - vitamin D deficiency 257–263
- Myeloma, immunoglobulin light chain 113–120
- Myocardium
- ouabain 415–420
 - pentobarbitone anaesthesia 549–551
- Natriuresis, urine reinfusion 187–193
- Natriuretic factor 187–193
- Nephrectomy
- acid–base changes 19–23
 - renal hypertension 25–29
- Nerve conduction velocity in liver disease 31–37
- Neurogenic activity, renal hypertension 25–29
- Neutrophil granulocytes
- intravascular senescence 453–460
 - tissue injury 295–303
- Nitrogen balance, premature infants 535–544
- Noradrenaline
- clonidine 509–514
 - essential hypertension 339–344
 - sleep 509–514

- Oligosaccharide units from mucus glycoproteins 445–451
- Osteoporosis, primary, parathyroid function 167–171
- Ouabain on myocardium 415–420
- Oxalate, urinary 285–288
- Oxygen breathing, asthma 389–396
- Parathyroid gland, primary osteoporosis 167–171
- Parathyroid hormone fragments 435–443
- primary osteoporosis 167–171
- Pentobarbitone anaesthesia 549–551
- Peptide hydrolases
- amino acids 521–527
 - intestinal 521–527, 529–534
 - rectal mucosa 295–303
- Peptides
- initiation 221–223
 - intestinal absorption 217–220
 - intestinal hydrolysis 529–534
 - intestinal transport 521–527
- Peptiduria
- Fanconi syndrome 277–279
- pH, intracellular 19–23
- Phlorhizin, renal transport 367–374
- Phosphate
- absorption and sodium lactate 125–127
 - renal transport 367–374
- Plasma renin activity
- β -adrenoreceptor stimulation 13–18
 - renal hypertension 25–29, 47–52
- Porphobilinogen 63–70
- Porphyrin biosynthesis 63–70
- Potassium
- anaesthesia 549–551
 - excretion in renal hypertension 47–52
 - intracellular 549–551
 - membrane permeability 289–293*
 - myocardium exchange 415–420
 - sodium pump 289–293*
- Premature infants, muscle protein degradation 535–544
- Proline, Fanconi syndrome 277–279
- Propranolol, ventilation 465–468
- Prostaglandins, inhibition of synthesis 359–365
- Protein
- metabolism and ethanol 481–490*
 - renal transport 113–120
 - skeletal muscle 221–223, 535–544
 - urinary calculi formation 285–288
 - whole-body turnover 281–283
- Pseudohypoparathyroidism 435–443
- Quadriceps muscle
- function in thyroid disorders 375–384
- Regional enteritis mucosal enzymes 295–303
- Regulator for infusions 515–520
- Relaxation rate, skeletal muscle 375–384
- Renal hypertension *see* Hypertension, renovascular
- Renin
- activation by kallikrein 351–357
 - angiotension II antagonist 461–463
 - binding substance 345–350
 - dietary sodium 173–179
 - higher-molecular-weight form 345–350
 - plasma interaction 233–240
 - saralasin 71–81
- Resistance, flow 515–520
- Respiratory failure 389–396
- Salt-free diet 225–231
- Saralasin ([$\text{Sar}^1, \text{Ala}^8$]angiotensin II)
- angiotensin receptors 71–81
 - renal hypertension 25–29
 - renin release 13–18
- Sarcoplasmic reticulum, vitamin D deficiency 257–263
- Scheie syndrome 265–272
- Seasonal variation in plasma vitamin D 473–476
- Sex difference, plasma amino acids 211–215
- Sino-aortic baroreflex 241–247
- Skeletal muscle *see* Muscle
- Sleep
- clonidine and sympathetic activity 509–514
- Sodium
- anaesthesia 549–551
 - excretion in renal hypertension 47–52
 - excretion on low-sodium diet 225–231
 - intracellular 549–551
 - intravenous 225–231
 - pump 289–293*
 - renal angiotensin II 173–179
 - renal transport 367–374
 - transport disorders 289–293*
- Spleen
- impaired function 129–137*
 - porphyrin biosynthesis 63–70
- Starvation, bilirubin 327–337
- Succinyl-CoA synthetase, bovine congenital erythropoietic porphyria 63–70
- Sucrase-isomaltase deficiency, congenital 181–185
- Sympathetic nervous activity, essential hypertension 339–344

- Tetrahydroaldosterone, urinary excretion 409–414
- Tetrapeptide, intestinal transport 1–11
- Transcobalamins, cobalamin distribution 139–144
- Transplant, renal 473–476
- Transport
- active 289–293*
 - amino acids 521–527
 - disorders 289–293*
 - intestinal 1–11
 - phlorhizin 367–374
 - renal 113–120, 367–374
- Triacylglycerol
- kidney transplantation 155–165
 - renal failure 155–165
- Troponin C, vitamin D deficiency 257–263
- Tubular absorption *see* Absorption, renal
- Uraemia, plasma lipase 155–165
- Urea
- diuresis by urine reinfusion 187–193
 - uretersigmoid anastomosis 305–312
- Ureterosigmoid anastomosis 305–312
- Uric acid, urinary 285–288
- Urine
- free aldosterone 409–414
 - reinfusion diuresis and natriuresis 187–193
- Uroporphyrin, porphyrin biosynthesis 63–70
- Uroporphyrinogen synthase, bovine congenital erythropoietic porphyria 63–70
- Valine, whole-body protein turnover 281–283
- Vein
- infusion flow 515–520
 - noradrenaline concentration 545–547
- Venous pressure 515–520
- Ventilation-perfusion ratios 389–396
- Ventilation, propranolol 465–468
- Vitamin B₁₂
- distribution 139–144
 - protein binding 295–303
- Vitamin D
- calcium absorption 121–123
 - deficiency 435–443
 - magnesium absorption 121–123
 - metabolism 93–101
 - muscle function 257–263
- Vitamin D-binding protein 167–171
- Water
- excretion in renovascular hypertension 47–52
 - lung 145–154

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.

Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption, intestinal
 - calcium 121–123
 - magnesium 121–123
 - peptides 217–220
 - vitamin D 121–123
- Absorption, renal, phosphate and sodium lactate 125–127
- Acid–base balance
 - pulmonary carbon dioxide equilibration 385–388
- Acidosis
 - hyperchloraemic 305–312
 - isolated kidney 103–111
 - nephrectomy 19–23
 - uretersigmoid anastomosis 305–312
- Adenocarcinoma, renal
 - mineralocorticoid receptors 421–425
- Adenosine triphosphate, sodium-transport disorders 289–293
- Adenylate cyclase, liver 313–325
- β -Adrenoreceptor
 - antagonists 241–247
 - blockade 203–210
 - isoprenaline stimulation 13–18
- Age, hypertensive responses 273–275
- Airway conductance 397–400
- Airway resistance 397–400
- Albumin, serum, pulmonary water compartments 145–154
- Alcohol, hepatic metabolism 481–490*
- Aldosterone
 - angiotensin II antagonist 461–463
 - receptors in renal adenocarcinoma 421–425
 - urinary excretion 409–414
- Aldosterone-18-glucuronide, urinary excretion 409–414
- Alkalosis, pulmonary carbon dioxide equilibration 385–388
- Alveolar–arterial difference 385–388
- Amino acids
 - intestinal transport 521–527
 - sex difference in plasma concentrations 211–215
 - skeletal muscle proteins 221–223
- δ -Aminolaevulinate dehydratase, bovine congenital erythropoietic porphyria 63–70
- δ -Aminolaevulinate synthase, bovine congenital erythropoietic porphyria 63–70
- Aminopeptidase, jejunal 1–11
- Ammonia
 - excretion in uretersigmoid anastomosis 305–312
 - metabolism of isolated kidney 103–111
- Anaemia, inflammation 453–460
- Anaesthesia
 - pentobarbitone 549–551
 - renal haemodynamics 469–471
- Angiotensin II
 - antagonist 25–29, 71–81, 461–463
 - inhibition of formation 53–62
 - kidney 173–179
- Angiotensin III
 - isoprenaline 401–407
- Antidiuresis, hydrochlorothiazide 427–434
- Arterial pressure
 - indometacin 359–365
 - renin 13–18
- Arterial pressure *see also* Hypertension
- Artery, noradrenaline concentration 545–547
- Aspartate, whole-body protein turnover 281–283
- Asthma
 - basophils, eosinophils and histamine 39–45
 - blood gases 389–396
- Asucrasia 181–185
- Baroreflex, sino-aortic 241–247
- Basophils, asthma 39–45
- Bayes' theorem 477–479
- Bence-Jones protein, isolated kidney 113–120
- Bicarbonate
 - excretion in uretersigmoid anastomosis 305–312
 - metabolism of isolated kidney 103–111
- Bile acid clearance 499–508
- Bilirubin, metabolism 327–337
- Biochemical discrimination, Hurler and Scheie syndromes 265–272
- Blood flow, general anaesthesia 469–471

Subject Index

- Blood pressure
 indomethacin 359–365
 renin 13–18
- Blood pressure *see also* Hypertension
- Bone marrow, porphyrin biosynthesis 63–70
- Bone
 acid-base buffering 19–23
 femur fractures in elderly 93–101
 osteoporosis 167–171
- Brush border, intestinal
 disaccharidases 181–185
 α -glucosidase 181–185
 peptide hydrolysis 217–220
- Bull with congenital erythropoietic porphyria 63–70
- Calcium
 absorption and vitamin D 121–123
 balance studies 89–92
 kinetics 93–101
 parathyroid hormone 435–443
 protein and urinary output 285–288
- Calculi, urinary
 dietary protein 285–288
- Carbon dioxide
 propranolol 465–468
 pulmonary equilibration 385–388
- Cardiac muscle *see* Myocardium
- Catecholamines
 excretion 339–344
 metabolism 203–210
 saralasin 71–81
- Cell-membrane permeability 289–293*
- Cholestasis 499–508
- Cholic acid clearance 499–508
- Chromic chloride, calcium balance studies 89–92
- Chromium sesquioxide, calcium balance studies 89–92
- Clonidine
 blood pressure 195–201
 sympathetic activity during sleep 509–514
- Cobalamin
 endogenous 139–144
- Colchicine
 acid-base balance 19–23
- Colitis, mucosal enzymes 295–303
- Colon, pathogenesis of hyperchloraemic acidosis 305–312
- Congenital porphyria, enzymes 63–70
- Contraction, myocardium 415–420
- Converting enzyme
 renal hypertension 53–62
 sodium intake 173–179
- Covariance analysis of airway resistance 397–400
- Creatinine, premature infants 535–544
- Cysteine–homocysteine, plasma concentrations 211–215
- Cystic fibrosis with meconium ileus 445–451
- Cytosol, kidney renin 345–350
- Deoxycorticosterone, hypertension 203–210
- Dexamethasone binding in renal adenocarcinoma 421–425
- Diabetes insipidus
 hydrochlorothiazide 427–434
 hypertension 273–275
- Diagnosis by elimination 477–479
- Diet
 low-sodium 225–231
 protein and urinary calculi 285–288
- 2,4-Dinitrophenol inhibition of intestinal absorption 217–220
- Diphosphonate
 acid-base balance 19–23
 skeletal muscle 257–263
- Disaccharidases, jejunal 181–185
- Diuresis, urine reinfusion 187–193
- Diuretics, immunoglobulin light chain in kidney 113–120
- Electroencephalography, peripheral nerve function 31–37
- Electrolytes, anaesthesia 549–551
- Endoplasmic reticulum, hepatic 491–497
- Energy turnover 375–384
- Enterocyte, subcellular fractionation 181–185
- Eosinophils, asthma 39–45
- Erythrocyte, morphology in hypoplasia 129–137*
- Ethanol, hepatic metabolism 481–490*
- Exercise
 dynamic 545–547
 isometric 545–547
- External radioactivity counting 145–154
- Fanconi syndrome 277–279
- Femur, fractures in elderly 93–101
- Ferrokinetics 453–460
- Fracture, bone, in elderly 93–101
- Functional residual capacity 397–400
- Galactose
 blood glucose 249–256
 plasma insulin 249–256
- Gilbert's disease 491–497

- Gluconeogenesis, acidosis in isolated kidney 103–111
- Glucose transport, renal 367–374
- Glutamine, metabolism in isolated kidney 103–111
- Glycine, whole-body protein turnover 281–283
- Glycocholic acid clearance 499–508
- Glycoproteins
- meconium mucus 445–451
 - metabolism and ethanol 481–490*
- Glycyl-L-leucine hydrolysis and transport 521–527
- Gunn rat, unconjugated hyperbilirubinaemia 327–337
- Haemodialysis, plasma 25-hydroxy-vitamin D 473–476
- Haemodynamics, renal 469–471
- Heparin, plasma lipases 155–165
- Hip replacement, intravenous galactose 249–256
- Histamine, asthma 39–45
- Homocystinuria and cysteine–homocysteine 211–215
- Hormones
- insulin 221–223
 - parathyroid hormone 167–171, 435–443
 - thyroxine 83–88
- Hurler syndrome 265–272
- Hydrochlorothiazide 427–434
- 18-Hydroxycorticosterone, urinary excretion 409–414
- Hydroxyproline, Fanconi syndrome 277–279
- 25-Hydroxy-vitamin D
- femur fractures in elderly 93–101
 - primary osteoporosis 167–171
 - seasonal variation 473–476
- Hyperaldosteronism 409–414
- Hyperbilirubinaemia
- hereditary 491–497
 - unconjugated 327–337
- Hypercapnia
- chronic 389–396
 - propranolol 465–468
- Hyperparathyroidism 435–443
- Hypertension
- β -adrenoceptor antagonists 241–247
 - age 273–275
 - aldosterone excretion 409–414
 - angiotensin II antagonist 461–463
 - clonidine 195–201
 - indomethacin 359–365
 - outpatients 339–344
- Hypertension, experimental
- aortic ligation 25–29
- Hypertension, experimental
- deoxycorticosterone salt 203–210
 - neurogenic activity 25–29
 - renal, Goldblatt one-kidney one-clip 53–62
 - renal, Goldblatt two-kidney one-clip 47–52, 53–62, 71–81
- Hypertension, renovascular
- angiotensin blockade 53–62, 71–81
 - plasma renin activity 47–52
 - potassium excretion 47–52
 - sodium excretion 47–52
 - water excretion 47–52
- Hyperthyroidism, quadriceps function 375–384
- Hyposplenism 129–137*
- Hypothyroidism
- plasma lipoproteins 83–88
 - quadriceps function 375–384
- Hypoxaemia 389–396
- α -L-Iduronidase, Hurler and Scheie syndromes 265–272
- Immune responses, spleen 129–137*
- Immunoglobulin light chain, isolated kidney 113–120
- Indomethacin 359–365
- Injury
- intravenous galactose 249–256
 - neutrophil granulocytes 295–303
- Insulin, skeletal muscle protein synthesis 221–223
- Intestine
- amino acid transport 521–527
 - dipeptide hydrolases 529–534
 - malabsorption 181–185
 - peptide absorption 217–220
 - subcellular fractionation 181–185
 - transport 1–11, 521–527
- Intravenous infusions 225–231, 515–520
- Isomaltase, intestinal 181–185
- Isoprenaline, angiotensin III 401–407
- Jejunum
- aminopeptidase 1–11
 - disaccharidases 181–185
 - subcellular fractionation 181–185
 - transport 1–11
- Juxtaglomerular apparatus 173–179
- Kallikrein
- inhibitor 351–357
 - renin activation 351–357
- Kidney
- acid–base changes after nephrectomy 19–23
 - ammonia production 103–111
 - anaesthesia and haemodynamics 469–471

- Kidney**
- angiotensin II 173–179
 - blood flow 71–81
 - cortical homogenate renin 345–350
 - failure 155–165, 435–443
 - glucose transport 367–365
 - immunoglobulin light chain 113–120
 - indomethacin 359–365
 - juxtaglomerular apparatus 173–179
 - mineralocorticoid receptors 421–425
 - phosphate absorption and lactate 125–127
 - phosphate transport 367–374
 - plasma 25-hydroxy-vitamin D 473–476
 - porphyrin biosynthesis 63–70
 - protein transport 113–120
 - proximal tubular function 427–434
 - renin secretion 233–240
 - sodium transport 367–374
 - transplantation and lipases 155–165
- Kidney disease**
- chronic renal failure 155–165, 435–443
 - immunoglobulin light chain 113–120
 - plasma 25-hydroxy-vitamin D 473–476
- Lactase, intestinal 181–185
- Lactate, sodium, phosphate renal absorption 125–127
- Lactoferrin turnover 453–460
- Leucine, whole-body protein turnover 281–283
- Leucocytes
- asthma 39–45
 - tissue injury 295–303
- L-Leucylglycylglycylglycine, intestinal transport I–II
- Lipase, plasma 155–165
- Lipid
- hyperbilirubinaemia 327–337
 - metabolism and ethanol 481–490*
- Lipoprotein, plasma, primary hypothyroidism 83–88
- Liver
- adenylate cyclase system 315–325
 - bile acid clearance 499–508
 - ethanol 481–490*
 - foetal 313–325
 - function tests 31–37
 - hyperglycaemia 249–256
 - porphyrin biosynthesis 63–70
 - subcellular fractionation 491–497
- Liver disease
- bile acid clearance 499–508
 - cirrhosis 31–37, 313–325, 481–490*
 - Gilbert's syndrome 491–497
 - peripheral nerve function in 31–37
- Lung**
- carbon dioxide equilibration 385–388
 - functional residual capacity 397–400
 - volume 397–400
 - water compartments 145–154
- Lysosomes in Gilbert's syndrome 491–497
- Macula densa 173–179
- Magnesium, absorption and vitamin D 121–123
- Maleic acid, Fanconi syndrome 277–279
- Maltase, intestinal 181–185
- Mathematical analysis of clinical diagnosis 477–479
- Meconium mucus glycoproteins 445–451
- Membrane, liver 313–325
- Membrane digestion
- intestinal 217–220
 - permeability 289–293*
- Metabolism, calcium balance 89–92
- 3-Methylhistidine, premature infants 535–544
- Mineralocorticoid receptors in renal adenocarcinoma 421–425
- Mixed disulphide, plasma 211–215
- Mucus glycoproteins of meconium 445–451
- Muramidase, rectal mucosa 295–303
- Muscle-fibre types 375–384
- Muscle, skeletal
- energy turnover 375–384
 - fibre-type composition 375–384
 - pentobarbitone anaesthesia 549–551
 - protein degradation 535–544
 - protein synthesis 221–223
 - relaxation rate 375–384
 - thyroid disorders 375–384
 - vitamin D deficiency 257–263
- Myeloma, immunoglobulin light chain 113–120
- Myocardium
- ouabain 415–420
 - pentobarbitone anaesthesia 549–551
- Natriuresis, urine reinfusion 187–193
- Natriuretic factor 187–193
- Nephrectomy
- acid–base changes 19–23
 - renal hypertension 25–29
- Nerve conduction velocity in liver disease 31–37
- Neurogenic activity, renal hypertension 25–29
- Neutrophil granulocytes
- intravascular senescence 453–460
 - tissue injury 295–303
- Nitrogen balance, premature infants 535–544
- Noradrenaline
- clonidine 509–514
 - essential hypertension 339–344
 - sleep 509–514

- Oligosaccharide units from mucus glycoproteins 445–451
- Osteoporosis, primary, parathyroid function 167–171
- Ouabain on myocardium 415–420
- Oxalate, urinary 285–288
- Oxygen breathing, asthma 389–396
- Parathyroid gland, primary osteoporosis 167–171
- Parathyroid hormone fragments 435–443
- primary osteoporosis 167–171
- Pentobarbitone anaesthesia 549–551
- Peptide hydrolases
- amino acids 521–527
 - intestinal 521–527, 529–534
 - rectal mucosa 295–303
- Peptides
- initiation 221–223
 - intestinal absorption 217–220
 - intestinal hydrolysis 529–534
 - intestinal transport 521–527
- Peptiduria
- Fanconi syndrome 277–279
- pH, intracellular 19–23
- Phlorhizin, renal transport 367–374
- Phosphate
- absorption and sodium lactate 125–127
 - renal transport 367–374
- Plasma renin activity
- β -adrenoreceptor stimulation 13–18
 - renal hypertension 25–29, 47–52
- Porphobilinogen 63–70
- Porphyrin biosynthesis 63–70
- Potassium
- anaesthesia 549–551
 - excretion in renal hypertension 47–52
 - intracellular 549–551
 - membrane permeability 289–293*
 - myocardium exchange 415–420
 - sodium pump 289–293*
- Premature infants, muscle protein degradation 535–544
- Proline, Fanconi syndrome 277–279
- Propranolol, ventilation 465–468
- Prostaglandins, inhibition of synthesis 359–365
- Protein
- metabolism and ethanol 481–490*
 - renal transport 113–120
 - skeletal muscle 221–223, 535–544
 - urinary calculi formation 285–288
 - whole-body turnover 281–283
- Pseudohypoparathyroidism 435–443
- Quadriceps muscle
- function in thyroid disorders 375–384
- Regional enteritis mucosal enzymes 295–303
- Regulator for infusions 515–520
- Relaxation rate, skeletal muscle 375–384
- Renal hypertension *see* Hypertension, renovascular
- Renin
- activation by kallikrein 351–357
 - angiotension II antagonist 461–463
 - binding substance 345–350
 - dietary sodium 173–179
 - higher-molecular-weight form 345–350
 - plasma interaction 233–240
 - saralasin 71–81
- Resistance, flow 515–520
- Respiratory failure 389–396
- Salt-free diet 225–231
- Saralasin ([$\text{Sar}^1, \text{Ala}^8$]angiotensin II)
- angiotensin receptors 71–81
 - renal hypertension 25–29
 - renin release 13–18
- Sarcoplasmic reticulum, vitamin D deficiency 257–263
- Scheie syndrome 265–272
- Seasonal variation in plasma vitamin D 473–476
- Sex difference, plasma amino acids 211–215
- Sino-aortic baroreflex 241–247
- Skeletal muscle *see* Muscle
- Sleep
- clonidine and sympathetic activity 509–514
- Sodium
- anaesthesia 549–551
 - excretion in renal hypertension 47–52
 - excretion on low-sodium diet 225–231
 - intracellular 549–551
 - intravenous 225–231
 - pump 289–293*
 - renal angiotensin II 173–179
 - renal transport 367–374
 - transport disorders 289–293*
- Spleen
- impaired function 129–137*
 - porphyrin biosynthesis 63–70
- Starvation, bilirubin 327–337
- Succinyl-CoA synthetase, bovine congenital erythropoietic porphyria 63–70
- Sucrase-isomaltase deficiency, congenital 181–185
- Sympathetic nervous activity, essential hypertension 339–344

- Tetrahydroaldosterone, urinary excretion 409–414
- Tetrapeptide, intestinal transport 1–11
- Transcobalamins, cobalamin distribution 139–144
- Transplant, renal 473–476
- Transport
- active 289–293*
 - amino acids 521–527
 - disorders 289–293*
 - intestinal 1–11
 - phlorhizin 367–374
 - renal 113–120, 367–374
- Triacylglycerol
- kidney transplantation 155–165
 - renal failure 155–165
- Troponin C, vitamin D deficiency 257–263
- Tubular absorption *see* Absorption, renal
- Uraemia, plasma lipase 155–165
- Urea
- diuresis by urine reinfusion 187–193
 - uretersigmoid anastomosis 305–312
- Uretersigmoid anastomosis 305–312
- Uric acid, urinary 285–288
- Urine
- free aldosterone 409–414
 - reinfusion diuresis and natriuresis 187–193
- Uroporphyrin, porphyrin biosynthesis 63–70
- Uroporphyrinogen synthase, bovine congenital erythropoietic porphyria 63–70
- Valine, whole-body protein turnover 281–283
- Vein
- infusion flow 515–520
 - noradrenaline concentration 545–547
- Venous pressure 515–520
- Ventilation-perfusion ratios 389–396
- Ventilation, propranolol 465–468
- Vitamin B₁₂
- distribution 139–144
 - protein binding 295–303
- Vitamin D
- calcium absorption 121–123
 - deficiency 435–443
 - magnesium absorption 121–123
 - metabolism 93–101
 - muscle function 257–263
- Vitamin D-binding protein 167–171
- Water
- excretion in renovascular hypertension 47–52
 - lung 145–154